This inventor holds 1 USPTO granted patent. Top assignee: Pliva, Farmaceutska Industrija, Dionicko Drustvo. Active years: 2003.
Company Filing History:
Years Active: 2003
Title: Drazen Pavlović: Innovator in Pharmaceutical Chemistry
Introduction
Drazen Pavlović is a notable inventor based in Zagreb, Croatia. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on 3-deoxy-desmycosin derivatives. His research has implications for the development of new pharmaceutical compounds.
Latest Patents
Drazen Pavlović holds a patent for "3-deoxy-desmycosin derivatives and process for their preparation." This invention relates to derivatives of 3-deoxy desmycosin, where specific chemical processes are employed to create new compounds. The patent outlines a method that begins with triply protected desmycosin, involving oxidation at C-3, followed by optional hydrogenation and epoxidation, culminating in a reductive opening of the oxirane ring. This innovative approach also includes the conversion of triacetyl desmycosin into a 2,3-didehydro derivative through hydrogenation and mesylate intermediates.
Career Highlights
Drazen Pavlović is associated with Pliva, Farmaceutska Industrija, Dionicko Drustvo, a prominent pharmaceutical company in Croatia. His work at Pliva has allowed him to engage in cutting-edge research and development in the pharmaceutical sector. His contributions have been instrumental in advancing the understanding and application of desmycosin derivatives.
Collaborations
Drazen has collaborated with several talented individuals in his field, including Amalija Narandja and Nevenka Lopotar. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their shared research interests.
Conclusion
Drazen Pavlović is a distinguished inventor whose work on 3-deoxy-desmycosin derivatives showcases his expertise in pharmaceutical chemistry. His contributions continue to influence the development of new therapeutic compounds, highlighting the importance of innovation in the pharmaceutical industry.